Mereo BioPharma Group (MREO) Competitors $2.30 +0.17 (+7.98%) Closing price 04:00 PM EasternExtended Trading$2.37 +0.07 (+2.83%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MREO vs. ARDX, EVO, AUPH, BGM, OCUL, IOVA, SNDX, WVE, COLL, and ELVNShould you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Ardelyx (ARDX), Evotec (EVO), Aurinia Pharmaceuticals (AUPH), Qilian International Holding Group (BGM), Ocular Therapeutix (OCUL), Iovance Biotherapeutics (IOVA), Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry. Mereo BioPharma Group vs. Ardelyx Evotec Aurinia Pharmaceuticals Qilian International Holding Group Ocular Therapeutix Iovance Biotherapeutics Syndax Pharmaceuticals Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Mereo BioPharma Group (NASDAQ:MREO) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment. Does the MarketBeat Community believe in MREO or ARDX? Ardelyx received 484 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 80.30% of users gave Mereo BioPharma Group an outperform vote while only 67.46% of users gave Ardelyx an outperform vote. CompanyUnderperformOutperformMereo BioPharma GroupOutperform Votes5380.30% Underperform Votes1319.70%ArdelyxOutperform Votes53767.46% Underperform Votes25932.54% Does the media prefer MREO or ARDX? In the previous week, Ardelyx had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 7 mentions for Ardelyx and 4 mentions for Mereo BioPharma Group. Ardelyx's average media sentiment score of 0.89 beat Mereo BioPharma Group's score of 0.73 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MREO or ARDX? Mereo BioPharma Group has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Do analysts rate MREO or ARDX? Mereo BioPharma Group presently has a consensus price target of $7.71, indicating a potential upside of 235.40%. Ardelyx has a consensus price target of $10.61, indicating a potential upside of 120.15%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Mereo BioPharma Group is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Ardelyx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is MREO or ARDX more profitable? Mereo BioPharma Group has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. Mereo BioPharma Group's return on equity of 0.00% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A N/A N/A Ardelyx -11.73%-24.87%-10.51% Which has preferable earnings and valuation, MREO or ARDX? Mereo BioPharma Group has higher earnings, but lower revenue than Ardelyx. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$1M356.84-$29.47M-$0.06-38.33Ardelyx$333.62M3.44-$39.14M-$0.16-30.13 Do institutionals and insiders believe in MREO or ARDX? 62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 4.1% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 5.9% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryMereo BioPharma Group beats Ardelyx on 10 of the 17 factors compared between the two stocks. Remove Ads Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MREO vs. The Competition Export to ExcelMetricMereo BioPharma GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$356.84M$6.44B$5.28B$7.34BDividend YieldN/A3.24%5.11%4.31%P/E Ratio-38.336.8321.6917.75Price / Sales356.84230.62378.4897.65Price / CashN/A65.6738.1534.64Price / Book6.395.906.433.98Net Income-$29.47M$142.50M$3.20B$247.33M7 Day Performance25.68%7.94%5.08%4.44%1 Month Performance-12.55%-13.95%-9.65%-7.72%1 Year Performance-10.85%-10.03%10.92%1.30% Mereo BioPharma Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MREOMereo BioPharma Group1.854 of 5 stars$2.30+8.0%$7.71+235.4%-20.8%$356.84M$1M-38.3340High Trading VolumeARDXArdelyx4.2459 of 5 stars$4.45-2.2%$10.61+138.5%-31.4%$1.06B$333.62M-27.8190Analyst RevisionNews CoverageEVOEvotec1.1798 of 5 stars$2.97-2.9%$5.93+99.8%-53.4%$1.05B$777.05M0.004,200News CoverageGap UpAUPHAurinia Pharmaceuticals2.5901 of 5 stars$7.59-2.8%$11.50+51.5%+53.4%$1.04B$235.13M-50.60300News CoveragePositive NewsBGMQilian International Holding GroupN/A$10.62-0.9%N/AN/A$1.03B$25.10M0.00298Gap DownOCULOcular Therapeutix3.4539 of 5 stars$6.30-0.9%$16.38+159.9%-8.0%$1.00B$63.72M-4.77230IOVAIovance Biotherapeutics4.2403 of 5 stars$3.03+1.0%$20.25+568.3%-74.2%$993.47M$164.07M-2.03500Analyst ForecastNews CoverageHigh Trading VolumeSNDXSyndax Pharmaceuticals3.3534 of 5 stars$11.01-2.1%$36.20+228.8%-48.1%$947.34M$23.68M-3.03110WVEWave Life Sciences4.1799 of 5 stars$5.80-3.8%$22.60+289.7%+11.0%$890.22M$108.30M-5.23240Short Interest ↑Analyst RevisionCOLLCollegium Pharmaceutical4.1712 of 5 stars$27.38-2.7%$43.60+59.2%-23.7%$879.77M$631.45M11.80210Positive NewsGap DownELVNEnliven Therapeutics2.5626 of 5 stars$17.87-4.4%$38.75+116.8%-14.0%$875.70MN/A-9.4150 Remove Ads Related Companies and Tools Related Companies ARDX Competitors EVO Competitors AUPH Competitors BGM Competitors OCUL Competitors IOVA Competitors SNDX Competitors WVE Competitors COLL Competitors ELVN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MREO) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MREO Stock Free MREO Stock Alerts